

CORCEPT THERAPEUTICS INC
Form 8-K
September 12, 2007

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934.

Date of Report: September 11, 2007
(Date of earliest event reported)

Corcept Therapeutics Incorporated
(Exact name of registrant as specified in its charter)

DE

**(State or other jurisdiction
of incorporation) 000-50679**

(Commission File Number) 77-0487658

(IRS Employer

Identification Number)

149 Commonwealth Drive, Menlo Park, CA

(Address of principal executive offices) 94025

(Zip Code)

650-327-3270

(Registrant's telephone number, including area code)

Not Applicable

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events

On September 11, 2007 Corcept Therapeutics Incorporated issued a press release announcing that it has received notification from the Food and Drug Administration (FDA) that the FDA has opened the Investigational New Drug Application (IND) for CORLUX for the treatment of Cushing's Syndrome.

Item 9.01. Financial Statements and Exhibits

(a) Financial statements:

None

(b) Pro forma financial information:

None

(c) Shell company transactions:

None

(d) Exhibits

99.1 Press Release of Corcept Therapeutics Incorporated dated September 11, 2007

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 12, 2007

CORCEPT THERAPEUTICS INCORPORATED

By: /s/ Anne LeDoux

Anne LeDoux

Vice President & Controller

Exhibit Index **Exhibit No.** **Description** 99.1 Press Release of Corcept Therapeutics Incorporated dated September 11, 2007